Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Chris Viehbacher spoke out about the uncertain policy environment for life sciences companies, though he didn't single ...

8:52 AM ESTCommercial Real Estate Biogen walks away from Sage collab on essential tremor drug Biogen walks away from Sage collab on essential tremor drug ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Companies including Biogen Inc. and Eli Lilly & Co. have spent billions of dollars on developing potential treatments, while others including Novo Nordisk A/S and Roche AG are also investigating ...

which measured cognitive function using the Apple devices and just generated two-year data that was reported at this week’s DTx in Boston. The study had been billed as a key element in Biogen ...

Biogen Inc. is making cuts to its research organization as the Cambridge company focuses its resources on “external opportunities.” ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat ...

Biogen Inc. is fending off a lawsuit in the Delaware Chancery Court over its recent offer to buy out Sage Therapeutics, its ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Sage Therapeutics (NASDAQ:SAGE) has confirmed that the Alzheimer’s drug developer Biogen (NASDAQ:BIIB) has offered to buy all the outstanding shares of common stock that it currently does not ...

(Reuters) - Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in ...